USPTO trademark

SCRIBE THERAPEUTICS

Under examinationUSPTOWord markClass 5

"SCRIBE THERAPEUTICS" is a word mark owned by Scribe Therapeutics Inc., filed at the USPTO on July 31, 2026. It is under examination and covers class 5 (Pharmaceuticals).

Get this data via the API
Official USPTO record
SCRIBE THERAPEUTICS trademark as filed
As filed with the USPTO
Status
Under examination
Since July 31, 2026
Filed
July 31, 2026
Registered
Not yet
Expires
Not recorded
Application no.
50024120
Registration no.
Not yet
Office
USPTO
United States Patent and Trademark Office
Mark type
Word mark
1 class
Ownership

Who owns SCRIBE THERAPEUTICS

The owner and representative on file with the office.

Owner

Scribe Therapeutics Inc.

Alameda, United States

Representative

John Paul Oleksiuk

Cooley LLP

Goods and services

What the mark covers

The products and services SCRIBE THERAPEUTICS is filed for, grouped by Nice class.

  • Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in the prevention and treatment of diseases in human therapeutics, namely, diseases caused by genetic mutations and diseases and disorders for which gene modification would ameliorate or cure; Pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics, namely, for the prevention and treatment of diseases caused by genetic mutations and of diseases and disorders for which gene modification would ameliorate or cure; Gene therapy products, namely, biological preparations based on engineered cells for medical use for the treatment of diseases caused by genetic mutations and of diseases and disorders for which gene modification would ameliorate or cure related to cardiometabolic disease, cardiovascular disease, neuromuscular diseases, immuno-oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; Pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, namely, neurological disorders, Huntington's disease, amyotrophic lateral sclerosis (ALS), front temporal dementia, Alzheimer's, Parkinson's, ataxia, autism, epilepsy, and pain, and also for the prevention and treatment of cardiovascular, peripheral nervous system, endocrine, gastrointestinal, renal, genetic immunological, hepatic, infectious, inflammatory, metabolic, cardiometabolic, neuromuscular, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, and hematologic diseases and disorders, and cancer

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. New application office supplied data entered
  2. Application filing receipt mailed
  3. New application entered
FAQ

About SCRIBE THERAPEUTICS

Who owns the trademark "SCRIBE THERAPEUTICS"?

The USPTO trademark "SCRIBE THERAPEUTICS" (application 50024120) is owned by Scribe Therapeutics Inc.

What is the status of "SCRIBE THERAPEUTICS"?

Its status at the USPTO is: under examination.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull SCRIBE THERAPEUTICS and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019fbd6d-4843-754e-8632-3d013a86c47b
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019fbd6d-4843-754e-8632-3d013a86c47b",
  "object": "trademark",
  "mark_text": "SCRIBE THERAPEUTICS",
  "status": {
    "primary": "pending",
    "stage": "examining"
  },
  "office_code": "US",
  "application_number": "50024120",
  "filing_date": "2026-07-31",
  "nice_classes": [
    5
  ],
  "owners": [
    {
      "name": "Scribe Therapeutics Inc.",
      "entity_id": null
    }
  ]
}